Meetings - The ASCO Post

/ Immunotherapy Approaches in Muscle-Invasive Bladder Cancer

Case 3: Perioperative Strategies for a Patient With Muscle-Invasive Bladder Cancer and Borderline Renal Function

This is Part 3 of Immunotherapy Approaches in Muscle-Invasive Bladder Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. M...

bladder cancer

/ Immunotherapy Approaches in Muscle-Invasive Bladder Cancer

Case 2: Adjuvant Therapy in a Patient With Cisplatin-Ineligible, Pathologic Node-Positive Muscle-Invasive Bladder Cancer

This is Part 2 of Immunotherapy Approaches in Muscle-Invasive Bladder Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. M...

bladder cancer

/ Immunotherapy Approaches in Muscle-Invasive Bladder Cancer

Case 1: Neoadjuvant Therapy in a Patient in Muscle-Invasive Bladder Cancer With Squamous Differentiation

This is Part 1 of Immunotherapy Approaches in Muscle-Invasive Bladder Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. M...

Immunotherapy Approaches in Muscle-Invasive Bladder Cancer

Case 3: Perioperative Strategies for a Patient With Muscle-Invasive Bladder Cancer and Borderline Renal Function

Case 2: Adjuvant Therapy in a Patient With Cisplatin-Ineligible, Pathologic Node-Positive Muscle-Invasive Bladder Cancer

Case 1: Neoadjuvant Therapy in a Patient in Muscle-Invasive Bladder Cancer With Squamous Differentiation

Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma

Early-Life Exposure to Environmental Carcinogens May Increase Risk of Pediatric Papillary Thyroid Cancer

Metabolic Syndrome May Increase Risk of Cancer Recurrence Subsequent Mortality Among Breast Cancer Survivors

Activity of ROS1 TKI in NSCLC

Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation